| ABSTRACT Objective:To investigate the occurrence and security of major adverse cardiovascular events (MACE) in the application of hydrochloride tirofiban in elderly patients with NSTEMI.Methods:92 elderly patients with NSTEMI who did not accept percutaneous coronary intervention (PCI) were selected in October 2009 to May 2012, aged 60 to 77 years old and randomly divided into the observation group (47 cases) and the controlled group (45 cases). Besides the conventional drug treatment, the observation group were treated with hydrochloride tirofiban injection with an intravenous micro pump continuously pumping into the load of 0.4 mg·kg-1·min-1, 30 min after 0.1 mg·kg-1·min-1, which sustained 24 48 hours. Such occurrences as cardiogenic sudden death, non fatal myocardial infarction, recurrent angina, and bleeding complications were observed 48 hours and 30 day MACE after the treatment. Results:The MACE incidence was significantly lower 48 hours and 30 days after the treatment with tirofiban in the observation group than those of the controlled group (2.12% vs. 15.52%,10.63% vs 28.89%). There was a statistically significant difference(P<0.05). Only some bleeding complications were found at gums (8 cases) and some skin points (6 cases). Conclusion: Hydrochloride tirofiban effectively reduced the incidence of elderly patients with NSTEMI MACE and improved the outcome of their recovery with better security, but without any serious bleeding complications. |
